NasdaqGS:ICPT

Stock Analysis Report

Executive Summary

Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases.

Snowflake

Fundamentals

High growth potential with mediocre balance sheet.

Share Price & News

How has Intercept Pharmaceuticals's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: ICPT's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

4.3%

ICPT

3.2%

US Biotechs

0.5%

US Market


1 Year Return

-21.1%

ICPT

11.1%

US Biotechs

16.1%

US Market

Return vs Industry: ICPT underperformed the US Biotechs industry which returned 11.1% over the past year.

Return vs Market: ICPT underperformed the US Market which returned 16.1% over the past year.


Shareholder returns

ICPTIndustryMarket
7 Day4.3%3.2%0.5%
30 Day25.9%11.1%3.9%
90 Day42.2%9.1%6.6%
1 Year-21.1%-21.1%12.1%11.1%18.7%16.1%
3 Year-24.2%-24.2%18.7%14.9%47.2%37.7%
5 Year-42.4%-42.4%5.4%0.5%61.5%43.7%

Price Volatility Vs. Market

How volatile is Intercept Pharmaceuticals's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Intercept Pharmaceuticals undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: ICPT ($86.59) is trading below our estimate of fair value ($253.73)

Significantly Below Fair Value: ICPT is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: ICPT is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: ICPT is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate ICPT's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: ICPT is overvalued based on its PB Ratio (21.7x) compared to the US Biotechs industry average (3x).


Next Steps

Future Growth

How is Intercept Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 18 analysts?

59.5%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: ICPT is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.7%).

Earnings vs Market: ICPT is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: ICPT's is expected to become profitable in the next 3 years.

Revenue vs Market: ICPT's revenue (40.5% per year) is forecast to grow faster than the US market (7.3% per year).

High Growth Revenue: ICPT's revenue (40.5% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if ICPT's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Intercept Pharmaceuticals performed over the past 5 years?

-9.7%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: ICPT has high quality earnings.

Growing Profit Margin: ICPT is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: ICPT is unprofitable, and losses have increased over the past 5 years at a rate of -9.7% per year.

Accelerating Growth: Unable to compare ICPT's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ICPT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (86.5%).


Return on Equity

High ROE: ICPT has a negative Return on Equity (-255.88%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is Intercept Pharmaceuticals's financial position?


Financial Position Analysis

Short Term Liabilities: ICPT's short term assets ($769.1M) exceeds its short term liabilities ($140.0M)

Long Term Liabilities: ICPT's short term assets ($769.1M) exceeds its long term liabilities (531.4M)


Debt to Equity History and Analysis

Debt Level: ICPT's debt to equity ratio (401.8%) is considered high.

Reducing Debt: Insufficient data to determine if ICPT's debt to equity ratio has reduced over the past 5 years.


Balance Sheet

Inventory Level: ICPT has a low level of unsold assets or inventory.

Debt Coverage by Assets: ICPT's debt is covered by short term assets (assets are 1.5x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ICPT has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if ICPT has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is Intercept Pharmaceuticals's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.4%markettop25%3.7%industryaverage2.1%forecastin3Years0%

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate ICPT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate ICPT's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ICPT's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ICPT's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of ICPT's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of Intercept Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?

2.8yrs

Average management tenure


CEO

Mark Pruzanski (51yo)

17.8yrs

Tenure

US$4,525,959

Compensation

Dr. Mark Pruzanski, M.D., founded Intercept Pharmaceuticals, Inc. in 2003 and has been its Chief Executive Officer and President since 2002. Dr. Pruzanski serves as the President and Chief Executive Office ...


CEO Compensation Analysis

Compensation vs Market: Mark's total compensation ($USD4.53M) is about average for companies of similar size in the US market ($USD5.09M).

Compensation vs Earnings: Mark's compensation has been consistent with company performance over the past year.


Management Age and Tenure

2.8yrs

Average Tenure

50yo

Average Age

Experienced Management: ICPT's management team is considered experienced (2.8 years average tenure).


Board Age and Tenure

4.7yrs

Average Tenure

59.5yo

Average Age

Experienced Board: ICPT's board of directors are considered experienced (4.7 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

BuyUS$314,08630 Aug 19
Samsara BioCapital LLC
EntityCompany
Shares5,207
Max PriceUS$60.32
BuyUS$4,498,57724 Aug 19
Samsara BioCapital LLC
EntityCompany
Shares67,784
Max PriceUS$67.12
BuyUS$100,20014 May 19
Luca Benatti
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares1,200
Max PriceUS$83.50
SellUS$557,12107 Dec 18
Lisa Morrison
EntityIndividual
Role
Senior Key Executive
President of International
Shares5,000
Max PriceUS$113.22
SellUS$78,802,50003 Dec 18
Genextra S.p.A.
EntityCompany
Shares750,000
Max PriceUS$105.07
SellUS$152,80730 Nov 18
Christian Weyer
EntityIndividual
Role
Senior Key Executive
Executive Vice President of Research & Development
Shares1,343
Max PriceUS$113.78

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 13%.


Management Team

  • Mark Pruzanski (51yo)

    Founder

    • Tenure: 17.8yrs
    • Compensation: US$4.53m
  • Jerry Durso (51yo)

    Chief Operating Officer

    • Tenure: 2.8yrs
    • Compensation: US$3.19m
  • Chris Weyer (49yo)

    Executive Vice President of Research & Development

    • Tenure: 2yrs
  • Mark Vignola (42yo)

    Executive Director

    • Tenure: 0yrs
  • Ryan Sullivan (43yo)

    General Counsel & Secretary

    • Tenure: 1.8yrs
    • Compensation: US$3.24m
  • Sandip Kapadia (49yo)

    CFO, Treasurer & Principal Accounting Officer

    • Tenure: 3.3yrs
    • Compensation: US$1.88m
  • Lisa Morrison (51yo)

    President of International

    • Tenure: 3.3yrs
    • Compensation: US$1.93m
  • Gail Cawkwell (57yo)

    Senior Vice President of Medical Affairs

    • Tenure: 1.8yrs
    • Compensation: US$2.21m
  • Richard Kim (50yo)

    President of U.S. Commercial & Strategic Marketing

    • Tenure: 4.3yrs
  • David Ford (50yo)

    Chief Human Resources Officer

    • Tenure: 2.5yrs
    • Compensation: US$1.91m

Board Members

  • Glenn Sblendorio (63yo)

    Independent Director

    • Tenure: 5.8yrs
    • Compensation: US$354.37k
  • Dan Welch (61yo)

    Independent Director

    • Tenure: 4yrs
    • Compensation: US$351.87k
  • Luca Benatti (58yo)

    Independent Director

    • Tenure: 5.3yrs
    • Compensation: US$349.37k
  • Gino Santini (62yo)

    Lead Independent Director

    • Tenure: 1.8yrs
    • Compensation: US$359.37k
  • Mark Pruzanski (51yo)

    Founder

    • Tenure: 17.8yrs
    • Compensation: US$4.53m
  • Paolo Fundaro (45yo)

    Independent Chairman of the Board

    • Tenure: 4.1yrs
    • Compensation: US$364.37k
  • Alan Hofmann

    Member of the Scientific Advisory Board

    • Tenure: 0yrs
  • Scott Friedman

    Member of the Scientific Advisory Board

    • Tenure: 0yrs
  • Massimo Pinzani

    Member of the Scientific Advisory Board

    • Tenure: 0yrs
  • Aldo Roda

    Member of the Scientific Advisory Board

    • Tenure: 0yrs

Company Information

Intercept Pharmaceuticals, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Intercept Pharmaceuticals, Inc.
  • Ticker: ICPT
  • Exchange: NasdaqGS
  • Founded: 2002
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$2.834b
  • Shares outstanding: 32.73m
  • Website: https://www.interceptpharma.com

Number of Employees


Location

  • Intercept Pharmaceuticals, Inc.
  • 10 Hudson Yards
  • 37th floor
  • New York
  • New York
  • 10001
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ICPTNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDOct 2012
I4PDB (Deutsche Boerse AG)YesCommon StockDEEUROct 2012
ICPT *BMV (Bolsa Mexicana de Valores)YesCommon StockMXMXNOct 2012

Biography

Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases. It markets Ocaliva, an farnesoi ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/11/21 00:42
End of Day Share Price2019/11/20 00:00
Earnings2019/09/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.